Aminoglycoside nephrotoxicity: a paradigm in toxicodynamic research

Paul M. Tulkens, MD, PhD
Cellular and Molecular Pharmacology Unit
Université catholique de Louvain, Brussels, Belgium

www.facm.ucl.ac.be

These slides will be available on http://www.facm.ucl.ac.be ➔ Lectures
What aminoglycosides?
(in one structure [of the lead compound] and 4 lines)

- polyaminated, hydrophilic
- broad spectrum (mostly Gram-negative), highly bactericidal
- predictable pharmacokinetics (no metabolism; renal excretion only)
- resistance remains low in most set-ups (many semi-synthetic derivatives with activity against resistance strains)
- parenteral administration only (no gut resorption)
You said nephrotoxicity?

- Typing "(gentamicin OR aminoglycoside*) AND nephrotoxicity" on PubMed will yield 1540 papers (among which 229 reviews), with the first one in 1969... (gentamicin was introduced in the clinics in 1967...)

- Controversies were immediate since among the 6 first papers, two say opposite things:

- Perhaps the true was:
Aminoglycoside nephrotoxicity: it's all how you look at it...

Patients with nephrotoxic reaction after treatment with gentamicin

- **young volunteers**
  - Smith et al., 1982

- **random hospital populat.**
  - Smith et al., 1980

- **critically-ill patients**
  - Plaut et al., 1979

% of patients experiencing nephrotoxicity

All those patients were under close monitoring...
What was monitoring aminoglycosides on those times?

- avoid high peaks ... to reduce toxicity
- get sufficiently high trough levels ... to get efficacy

Very small range, isn’t it?

From an "Abbott TdX booklet" (1976) to which I contributed...
Belgian guidelines kept this until 2000...

Toxicodynamics (session 72) - ICAAC/IDSA Sunday, Oct 26, 2008
So, now you have two series of questions ...

• Is it toxic or not? If yes, please
  – explain the mechanism...
  – what are the risk factors?

• Can we do something to reduce this toxicity? If yes,
  – can we put in clinical practice?
  – or, perhaps, in drug development?
Aminoglycoside toxicity cascade (1st version)...

From: Tulkens, 1986 Amer. J Med. 80(Suppl 6B);105-114
Aminoglycoside entry in proximal tubular cells is via brush border binding *...

Silverblatt & Kuehen, Kidney Intern., 1979

binding to

- megalin (Moeströp et al., 1995)
- acidic phospholipids (Humes et al, 1983)
Gentamicin accumulates in lysosomes of proximal tubular cells

Schmitz et al., J. Biol. Chem. 277:618-622, 2002
Mice deficient in megalin do not accumulate gentamicin in kidney

Schmitz et al., J. Biol. Chem. 277:618-622, 2002
What happens to the kidney when aminoglycosides are taken up by proximal tubule?
Compare control and treated animals…
Treated animal (gentamicin 10 mg/kg) …
Intralysosomal gentamicin binds to phospholipids and cause phospholipidosis

Tulkens, Am. J. Med. 80:105-114, 1986
Phospholipidosis is related to the binding of gentamicin to acidic phospholipids and subsequent inhibition of lysosomal phospholipases.

Adapted from Brasseur et al., 1989

P. Lambricht, 1991
Towards a mechanism …*

1. binding to brush border (via megalin / ac. phospholipids)
2. accumulation in lysosomes and phospholipidosis (binding)
3. phospholipiduria (cell death / exocytosis)
Aminoglycoside toxicity: a 2\textsuperscript{d} view…

FIG. 1. Ultrastructural alterations induced in proximal tubular cells during aminoglycoside treatment. (A) Control. Changes detected early on and at low doses (B) consist mainly of the enlargement of lysosomes, which most likely occurs by fusion of preexisting structures and which is caused by the progressive deposition of polar lipids which adopt a concentric lamellar disposition (myelin-like structures, most commonly referred to as myeloid bodies); the other subcellular structures are usually well preserved. Later changes or changes observed with high doses (C) include the apparent rupture of lysosomes (with the release of myeloid bodies in the cytosol), extensive mitochondrial swelling and damage, dilation of the endoplasmic reticulum cisternae, shedding of the apical brush-border villi, pericellular membrane discontinuities, and the occurrence of amitotic nuclei. These alterations do not necessarily coexist in all cells. The figure is adapted from reference 76 and is based on the typical descriptions given in references 38, 40, 71, 76, 77, 127, and 138.

Apoptosis in kidney and renal cells as first sign of toxicity…

Morphological changes in rat renal cortex (A,C,D) upon treatment with gentamicin at low doses (10 mg/kg; 10 days) and in cultured LLC-PK1 renal cells (B) upon incubation with gentamicin (under conditions causing a drug accumulation similar to that observed in rat renal cortex of the animals treated as indicated in A, B, and C [approx. 10 µg/g;]

Servais et al. In: Toxicology of the Kidney (Target Organ Toxicology Series), 2004, chap. 16, pp 635-685,
Apoptosis and phospholipidosis in kidney cortex: an early sign of toxicity?

rats treated with therapeutically-relevant doses of aminoglycosides (*)


phospholipids

apoptosis
What do you mean by therapeutically-relevant doses of aminoglycosides?

TABLE 1. Experimental groups, conditions of treatments, and relevance to the clinical use of aminoglycosides

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dose (mg/kg)(^a)</th>
<th>Duration (days)</th>
<th>Fold increase over:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clinical dose(^b)</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>10</td>
<td>4–10</td>
<td>~2</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>4–10</td>
<td>~4</td>
</tr>
<tr>
<td>Netilmicin</td>
<td>10</td>
<td>4–10</td>
<td>~1.7</td>
</tr>
<tr>
<td></td>
<td>20</td>
<td>4–10</td>
<td>~3.3</td>
</tr>
<tr>
<td>Amikacin</td>
<td>40</td>
<td>10</td>
<td>~2.7</td>
</tr>
<tr>
<td>Isepmicin</td>
<td>40</td>
<td>10</td>
<td>~2.7</td>
</tr>
</tbody>
</table>

\(^a\) Twice-a-day schedule (daily dose split into two administrations at 12-h intervals). This schedule (or even a three-times-a-day schedule) was long considered mandatory for aminoglycosides but is known to increase toxicities at both low and high doses in animals (38, 52). Data for patients are less definite, even though a trend toward less toxicity is commonly observed with a once-a-day schedule (21, 48).

\(^b\) Suggested maintenance doses for an adult patient with an estimated creatinine clearance of 90 ml/min (20) (gentamicin, 5.1; netilmicin, 6; and amikacin, 15 mg/kg, respectively) or based on the registered dosage in Belgium and many other countries for isepmicin.

\(^c\) Based on estimated ratio of areas under the serum concentration-time curve, AUC ratio, using the dose ratio defined in footnote \(b\) and assuming apparent half-lives of ~30 min in rats and ~120 min in humans (\(\beta\)-elimination phases).
Apoptosis is probably induced by disruption of gentamicin-loaded lysosomes

Fig. 4. Appearance of acridine orange-loaded LLC-PK1 cells in confocal microscopy. Cells were exposed to acridine orange (5 μg/ml) for 15 min and then returned to control medium for 3 h (A, B), or exposed to gentamicin (C and D, 3 mM, 3 h; E, 2 mM, 4 h) or MSDH (F, 25 μM, 3 h).

Electroporation allows to by-pass lysosomes and increases cell-susceptibility to gentamicin-induced apoptosis in cultured cells

Figure 1: Staining of nuclei of LLC-PK₁ cells by 4’,6’-diamidine-2’-phenylindole (DAPI). Incubated: cells were maintained for 24 h in the absence of gentamicin (no GEN) or in the presence of gentamicin (GEN) at the concentration shown (3 mM; 1.3 g/L). Electroporated: cells were electroporated in the absence (no GEN) or in the presence of gentamicin (GEN) at the concentration shown (0.03 mM; 13.9 mg/L), and examined 24 h later. In the absence of gentamicin, both electroporated and incubated cells show a diffuse finely reticulated staining characteristic of euchromatin of diploid interphase animal cells. In contrast, cells electroporated or incubated in the presence of gentamicin show typical changes associated with apoptosis, consisting in the condensation and fragmentation of the nuclear material.

Bypassing lysosomes in cultured cells …

Apoptosis in electroporated cells as a means to test for toxicity

FIG. 2. Apoptosis in electroporated cells. Cells were electroporated in the absence (controls) or in the presence of neomycin B, gentamicin, isepamicin, or amikacin and returned to aminoglycoside-free medium, and apoptotic nuclei were enumerated 24 h later. Values are means ± standard deviations (n = 3). Statistical analysis was performed by two-tailed analysis of variance (P < 0.01). All values for neomycin B and gentamicin, except those observed for the largest concentration tested (0.256 mM), are significantly different from those of the controls; isepamicin values observed for 0.192, 0.288, and 0.384 mM concentrations are significantly different from those of controls; amikacin values did not differ from control values. The 0.12 mM concentration corresponds to approximately 74 mg/liter for neomycin B, 56 mg/liter for gentamicin (taking into account the respective contents of the commercial gentamicin in C1, C1a, and C2 components), 68 mg/liter for isepamicin, and 70 mg/liter for amikacin. See the supplemental material for structures of tested compounds.

Gentamicin and apoptosis: an overview

- lysosomes
  - ROS
  - cathepsins?
- endosomes
- Golgi
- ER
- proteasome
  - degradation
- mitochondria
  - ROS
  - Bax
  - cyt. c
- DNA fragmentation
- caspase 3

Servais et al. 
Apoptosis 2007; 13:11-32

* how these questions are to be structured
Are they other mechanisms of toxicity proposed?

Yes, many others, but the questions are whether alterations described
• are primary (causative) or secondary
• are seen at therapeutically-meaningful doses and concentrations (PK/PD)
So, now you have two series of questions ...

• Is it toxic or not? If yes, please
  – explain the mechanism...
  – what are the risk factors?

• Can we do something to reduce this toxicity? If yes,
  – can we put in clinical practice?
  – or, perhaps, in drug development?
Risk factors in a nutshell...

**PROVEN, CLINICALLY RELEVANT RISK FACTORS IN AMINOGLYCOSIDE NEPHROTOXICITY***

*Patient-related*
  - Age
  - Large initial creatinine clearance
  - Impaired renal function (if dose not adjusted)
  - Liver disease
  - Critically ill state and shock
  - High tissue accumulation

*Treatment-related*
  - High peak levels**
  - Sustained elevated levels***
  - Total dose
  - Duration of treatment
  - Coadministration of other potentially nephrotoxic drugs (vancomycin, cephaloridine and perhaps cefalothin, but not other beta-lactams, amphotericin, cisplatin)
  - Coadministration of loop diuretics and volume-depleting agents

* Based partly on Refs. 9 and 55 and various reports on animal studies.
** For the schedule of administration considered. Thus, patients treated once a day may have much higher peak levels than patients treated three times a day, without signs of toxicity. Determination of standards for peak levels in the once-a-day regimen have, however, not yet been determined.
*** Usually determined 8 h after last administration; sustained levels usually related to inadequate elimination, tissue storage and/or too frequent dosing and are therefore highly indicative of potential toxicity.
So, now you have two series of questions ...

- **Is it toxic or not?** If yes, please
  - explain the mechanism...
  - what are the risk factors?
- **Can we do something to reduce this toxicity?** If yes,
  - can we put in clinical practice?
  - or, perhaps, in drug development?
### TABLE 2. Main approaches toward reduction of aminoglycoside nephrotoxicity*

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Compound</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>I. Decrease or prevention of drug accumulation by kidneys</strong></td>
<td></td>
</tr>
<tr>
<td>Intracellular complexation of aminoglycosides</td>
<td></td>
</tr>
<tr>
<td>Competition with or decrease in aminoglycoside binding to brush border</td>
<td>Ca(^{2+}) (diet supplementation [51] or vitamin D-induced hypercalcemia [21])</td>
</tr>
<tr>
<td>membrane</td>
<td>Lysine (81)</td>
</tr>
<tr>
<td>Competitors</td>
<td>Aminoglycosides (as their own competitors) (39)</td>
</tr>
<tr>
<td><strong>II. Prevention or decrease of lysosomal phospholipase inhibition</strong></td>
<td></td>
</tr>
<tr>
<td>Coadministration of agent preventing intralysosomal phospholipidosis</td>
<td>Polyspartic acid (55, 62)</td>
</tr>
<tr>
<td>Intralysosomal sequestration of aminoglycosides</td>
<td></td>
</tr>
</tbody>
</table>

Aminoglycoside toxicity is not linked to peak (alone)
Aminoglycoside accumulation is kidney is saturable at clinically meaningful concentrations * ...

* Giuliano et al., J. Pharm. Exp. Ther., 1986

this is where patients are in a q8h schedule !!
Néphrotoxicity and schedule of administration …
the first large scale clinical trial

• 141 predominantly elderly patients with severe bacterial infections.
• All patients received once-daily doses of 2 g ceftriaxone, in addition to netilmicin.

"Netilmicin-induced toxicity may be reduced by using once-daily dosing regimens and limiting the duration of treatment."

Is the once-a-day schedule used?

National survey of extended-interval aminoglycoside dosing (EIAD).
Chuck SK, Raber SR, Rodvold KA, Areff D.

• 500 acute care hospitals in the United States
• EIAD adopted in 3 of every 4 acute care hospitals
  – 4-fold increase since 1993
  – written guidelines for EIAD in 64% of all hospitals
• rationale
  – 87.1% : equal or less toxicity
  – 76.9% : equal efficacy
  – 65.6% : cost-savings
• dose: > 5 mg/Kg
• 47% used extended interval in case of decline in renal function (38% with Hartford nomogram)
Is the once-a-day schedule used?

Extended-interval dosing of gentamicin for treatment of neonatal sepsis in developed and developing countries.

Darmstadt GL, Miller-Bell M, Batra M, Law P, Law K.

Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD 21205, USA. gdarmsta@jhsph.edu

Serious bacterial infections are the single most important cause of neonatal mortality in developing countries. Case-fatality rates for neonatal sepsis in developing countries are high, partly because of inadequate administration of necessary antibiotics. For the treatment of neonatal sepsis in resource-poor, high-mortality settings in developing countries where most neonatal deaths occur, simplified treatment regimens are needed. Recommended therapy for neonatal sepsis includes gentamicin, a parenteral aminoglycoside antibiotic, which has excellent activity against gram-negative bacteria, in combination with an antimicrobial with potent gram-positive activity. Traditionally, gentamicin has been administered 2-3 times daily. However, recent evidence suggests that extended-interval (i.e. >24 hours) dosing may be applicable to neonates. This review examines the available data from randomized and non-randomized studies of extended-interval dosing of gentamicin in neonates from both developed and developing countries. Available data on the use of gentamicin among neonates suggest that extended dosing intervals and higher doses (>4 mg/kg) confer a favourable pharmacokinetic profile, the potential for enhanced clinical efficacy and decreased toxicity at reduced cost. In conclusion, the following simplified weight-based dosing regimen for the treatment of serious neonatal infections in developing countries is recommended: 13.5 mg (absolute dose) every 24 hours for neonates of >2,500 g, 10 mg every 24 hours for neonates of 2,000-2,499 g, and 10 mg every 48 hours for neonates of <2,000 g.

PMID: 18686550 [PubMed - indexed for MEDLINE]
Aminoglycoside prevention of toxicity …

**TABLE 2. Main approaches toward reduction of aminoglycoside nephrotoxicity**

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Compound</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. Decrease or prevention of drug accumulation by kidneys</td>
<td></td>
</tr>
<tr>
<td>Intracellular complexation of aminoglycosides</td>
<td></td>
</tr>
<tr>
<td>Competition with or decrease in aminoglycoside binding to brush border membrane</td>
<td></td>
</tr>
<tr>
<td>Competitors</td>
<td></td>
</tr>
<tr>
<td>Ca^{2+} (diet supplementation [51] or vitamin D-induced hypercalcemia [21])</td>
<td></td>
</tr>
<tr>
<td>Lysine (81)</td>
<td></td>
</tr>
<tr>
<td>Aminoglycosides (as their own competitors) (39)</td>
<td></td>
</tr>
<tr>
<td>II. Prevention or decrease of lysosomal phospholipase inhibition</td>
<td></td>
</tr>
<tr>
<td>Coadministration of agent preventing intralysosomal phospholipidosis</td>
<td>Polyaspartic acid (55, 62)</td>
</tr>
<tr>
<td>Intralysosomal sequestration of aminoglycosides</td>
<td></td>
</tr>
</tbody>
</table>


Conclusions *

• Aminoglycosides remain, and may become again potent and useful drugs against Gram (-) organisms if
  – appropriate resistance surveillance is in place
  – accepting that they need to be administered by intravenous route
  – toxicity is minimized by using a once-daily (extended interval) schedule and taking the known risk factors in due consideration...

• It should be possible to design/screen for new aminoglycosides with reduced toxicity based on our present knowledge of its mechanisms

• Medicinal chemistry is needed to find new ways to avoid resistance (enzyme-mediated drug inactivation and target mutation…); additional screening may be needed to avoid efflux … and renal uptake (antagonists ?) …

• new aminoglycosides made along these lines could be important drugs in the future because of the demise of many other classes towards Gram (-) organisms (β-lactams, fluoroquinolones, …)

* not all based on what I said, but I can expand if you wish …
Why not?
Aminoglycoside research present co-workers ...

Main former co-workers: